Neuralstem (CUR) is firmer Monday after the company reported mixed financial results for fiscal 2013.
Shares are up 2.73% at $3.64 near midday, with a 52-week range of $1.00 – $3.84.
The development-stage drug company said for fiscal 2013, net loss was $19.83 million or $0.27 per share, compared to a loss of $10.12 million or $0.17 per share in fiscal 2012. The Capital IQ consensus estimate is for a loss of $0.18 per share.
Revenue was $0.11 million, down from $0.41 million in the same quarter last year. Analysts were expecting revenues of $0.11 million.
Suggested Reading: Highest Grossing Movies
